Early Administration of SGLT2 Inhibitors in Hospitalized Patients: A Practical Guidance from the Current Evidence
ESC Heart Failure · 01.08.2025 · 12 (4) · 2631-2642
DOI: 10.1002/ehf2.15293 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ESC Heart Failure, online erschienen am 17.04.2025. Verfasst von Ruggero Mazzotta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Careggi University Hospital, Florence, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Hospitalization, Practice Guidelines as Topic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 inhibitors. The potential risk of side effects, like genito-urinary infections and interaction with other drugs, may often lead to delay the prescription of these drugs in the acute setting. However, several studies have demonstrated the safety and the prognostic impact of SGLT2 inhibitors in the hospitalized patient, suggesting that treatment initiation during hospitalization or early post-discharge may represent an ideal therapeutic option. In this review, we discuss the main trials on early administration of SGLT2 inhibitors in acute heart failure supporting early introduction of SGLT2 inhibitors to optimize heart failure treatment. The efficacy and safety of these drugs in patients with acute myocardial infarction are also discussed. Based on the review of existing evidences, a practical flowchart on early administration of SGLT2 inhibitors in the acute setting is proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Careggi University Hospital, Florence, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
- Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
- Arrhythmia and Electrophysiology Unit, Careggi University Hospital, Florence, Italy.
- Cardiovascular Diseases Unit, Cardio-Thoracic and Vascular Department, Le Scotte Hospital University of Siena, Siena, Italy.
Zitieren
APA
Mazzotta, R., Garofalo, M., Salvi, S., Orlandi, M., Marcaccini, G., Susini, P., Checchi, L., Palazzuoli, A., Di Mario, C., Pieroni, M., & Beltrami, M. (2025). Early Administration of SGLT2 Inhibitors in Hospitalized Patients: A Practical Guidance from the Current Evidence. ESC Heart Failure, 12(4), 2631-2642. https://doi.org/10.1002/ehf2.15293
Vancouver
Mazzotta R, Garofalo M, Salvi S, Orlandi M, Marcaccini G, Susini P, et al. Early Administration of SGLT2 Inhibitors in Hospitalized Patients: A Practical Guidance from the Current Evidence. ESC Heart Failure. 2025;12(4):2631-2642. doi:10.1002/ehf2.15293
BibTeX
@article{Mazzotta2025,
author = {Mazzotta, Ruggero and Garofalo, Manuel and Salvi, Samuele and Orlandi, Matteo and Marcaccini, Gianluca and Susini, Pietro and Checchi, Luca and Palazzuoli, Alberto and Di Mario, Carlo and Pieroni, Maurizio and Beltrami, Matteo},
title = {Early Administration of SGLT2 Inhibitors in Hospitalized Patients: A Practical Guidance from the Current Evidence},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {4},
pages = {2631--2642},
doi = {10.1002/ehf2.15293}
}
EUVIMED